( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

Mexico’s footcare landscape thrives on combined medical advancements and consumer-driven demands, pushing specialized product ...